Literature DB >> 12032337

Insight into the molecular basis of pathogen abundance: group A Streptococcus inhibitor of complement inhibits bacterial adherence and internalization into human cells.

Nancy P Hoe1, Robin M Ireland, Frank R DeLeo, Brian B Gowen, David W Dorward, Jovanka M Voyich, Mengyao Liu, Eugene H Burns, Derek M Culnan, Anthony Bretscher, James M Musser.   

Abstract

Streptococcal inhibitor of complement (Sic) is a secreted protein made predominantly by serotype M1 Group A Streptococcus (GAS), which contributes to persistence in the mammalian upper respiratory tract and epidemics of human disease. Unexpectedly, an isogenic sic-negative mutant adhered to human epithelial cells significantly better than the wild-type parental strain. Purified Sic inhibited the adherence of a sic negative serotype M1 mutant and of non-Sic-producing GAS strains to human epithelial cells. Sic was rapidly internalized by human epithelial cells, inducing cell flattening and loss of microvilli. Ezrin and moesin, human proteins that functionally link the cytoskeleton to the plasma membrane, were identified as Sic-binding proteins by affinity chromatography and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry analysis. Sic colocalized with ezrin inside epithelial cells and bound to the F-actin-binding site region located in the carboxyl terminus of ezrin and moesin. Synthetic peptides corresponding to two regions of Sic had GAS adherence-inhibitory activity equivalent to mature Sic and inhibited binding of Sic to ezrin. In addition, the sic mutant was phagocytosed and killed by human polymorphonuclear leukocytes significantly better than the wild-type strain, and Sic colocalized with ezrin in discrete regions of polymorphonuclear leukocytes. The data suggest that binding of Sic to ezrin alters cellular processes critical for efficient GAS contact, internalization, and killing. Sic enhances bacterial survival by enabling the pathogen to avoid the intracellular environment. This process contributes to the abundance of M1 GAS in human infections and their ability to cause epidemics.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12032337      PMCID: PMC124310          DOI: 10.1073/pnas.112039899

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  Hyaluronic acid capsule and the role of streptococcal entry into keratinocytes in invasive skin infection.

Authors:  H M Schrager; J G Rheinwald; M R Wessels
Journal:  J Clin Invest       Date:  1996-11-01       Impact factor: 14.808

2.  Replacement of threonine 558, a critical site of phosphorylation of moesin in vivo, with aspartate activates F-actin binding of moesin. Regulation by conformational change.

Authors:  L Huang; T Y Wong; R C Lin; H Furthmayr
Journal:  J Biol Chem       Date:  1999-04-30       Impact factor: 5.157

3.  Comparison of adherence to and penetration of a human laryngeal epithelial cell line by group A streptococci of various M protein types.

Authors:  M M Hagman; J B Dale; D L Stevens
Journal:  FEMS Immunol Med Microbiol       Date:  1999-03

4.  Hyaluronic acid capsule modulates M protein-mediated adherence and acts as a ligand for attachment of group A Streptococcus to CD44 on human keratinocytes.

Authors:  H M Schrager; S Albertí; C Cywes; G J Dougherty; M R Wessels
Journal:  J Clin Invest       Date:  1998-04-15       Impact factor: 14.808

Review 5.  Regulation of cortical structure by the ezrin-radixin-moesin protein family.

Authors:  A Bretscher
Journal:  Curr Opin Cell Biol       Date:  1999-02       Impact factor: 8.382

6.  High-frequency intracellular invasion of epithelial cells by serotype M1 group A streptococci: M1 protein-mediated invasion and cytoskeletal rearrangements.

Authors:  P E Dombek; D Cue; J Sedgewick; H Lam; S Ruschkowski; B B Finlay; P P Cleary
Journal:  Mol Microbiol       Date:  1999-02       Impact factor: 3.501

7.  Ezrin is an effector of hepatocyte growth factor-mediated migration and morphogenesis in epithelial cells.

Authors:  T Crepaldi; A Gautreau; P M Comoglio; D Louvard; M Arpin
Journal:  J Cell Biol       Date:  1997-07-28       Impact factor: 10.539

8.  Moesin, ezrin, and p205 are actin-binding proteins associated with neutrophil plasma membranes.

Authors:  K Pestonjamasp; M R Amieva; C P Strassel; W M Nauseef; H Furthmayr; E J Luna
Journal:  Mol Biol Cell       Date:  1995-03       Impact factor: 4.138

9.  Ezrin self-association involves binding of an N-terminal domain to a normally masked C-terminal domain that includes the F-actin binding site.

Authors:  R Gary; A Bretscher
Journal:  Mol Biol Cell       Date:  1995-08       Impact factor: 4.138

10.  Disruption of dynamic cell surface architecture of NIH3T3 fibroblasts by the N-terminal domains of moesin and ezrin: in vivo imaging with GFP fusion proteins.

Authors:  M R Amieva; P Litman; L Huang; E Ichimaru; H Furthmayr
Journal:  J Cell Sci       Date:  1999-01       Impact factor: 5.285

View more
  30 in total

1.  M types of group a streptococcal isolates submitted to the National Centre for Streptococcus (Canada) from 1993 to 1999.

Authors:  Gregory J Tyrrell; Marguerite Lovgren; Betty Forwick; Nancy P Hoe; James M Musser; James A Talbot
Journal:  J Clin Microbiol       Date:  2002-12       Impact factor: 5.948

2.  Genomic location and variation of the gene for CRS, a complement binding protein in the M57 strains of Streptococcus pyogenes.

Authors:  Michael Binks; David McMillan; Kadaba S Sriprakash
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

3.  Streptococcus pyogenes Ser/Thr kinase-regulated cell wall hydrolase is a cell division plane-recognizing and chain-forming virulence factor.

Authors:  Vijay Pancholi; Gregory Boël; Hong Jin
Journal:  J Biol Chem       Date:  2010-07-19       Impact factor: 5.157

4.  Effect of antibiotics on group A Streptococcus exoprotein production analyzed by two-dimensional gel electrophoresis.

Authors:  Megumi Tanaka; Tadao Hasegawa; Akira Okamoto; Keizo Torii; Michio Ohta
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

5.  Dynamics in prophage content of invasive and noninvasive M1 and M28 Streptococcus pyogenes isolates in The Netherlands from 1959 to 1996.

Authors:  Bart J M Vlaminckx; Frank H J Schuren; Roy C Montijn; Martien P M Caspers; M M Beitsma; Wim J B Wannet; Leo M Schouls; Jan Verhoef; Wouter T M Jansen
Journal:  Infect Immun       Date:  2007-04-23       Impact factor: 3.441

6.  drs (Distantly related sic) gene polymorphisms among emm12-type Streptococcus pyogenes isolates.

Authors:  Claudia M Brandt; Gerhard Haase; Barbara Spellerberg; Regina Holland; Rudolf Lütticken
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

7.  Analysis of the transcriptome of group A Streptococcus in mouse soft tissue infection.

Authors:  Morag R Graham; Kimmo Virtaneva; Stephen F Porcella; Donald J Gardner; R Daniel Long; Diane M Welty; William T Barry; Claire A Johnson; Larye D Parkins; Fred A Wright; James M Musser
Journal:  Am J Pathol       Date:  2006-09       Impact factor: 4.307

8.  Growth characteristics of and virulence factor production by group A Streptococcus during cultivation in human saliva.

Authors:  Samuel A Shelburne; Chanel Granville; Maria Tokuyama; Izabela Sitkiewicz; Payal Patel; James M Musser
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

9.  Genome-wide protective response used by group A Streptococcus to evade destruction by human polymorphonuclear leukocytes.

Authors:  Jovanka M Voyich; Daniel E Sturdevant; Kevin R Braughton; Scott D Kobayashi; Benfang Lei; Kimmo Virtaneva; David W Dorward; James M Musser; Frank R DeLeo
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-06       Impact factor: 11.205

10.  Species-specific interaction of Streptococcus pneumoniae with human complement factor H.

Authors:  Ling Lu; Zhuo Ma; T Sakari Jokiranta; Adeline R Whitney; Frank R DeLeo; Jing-Ren Zhang
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.